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Depression
epression—unipolar depression, clinical depres-
sion, or major depressive disorder (MDD)—is a severe
neuropsychiatric disorder that affects 350 million diag-
nosed patients and their families worldwide. The
National Institutes of Health (NIH) estimates that 60%
of people who commit suicide have MDD or another
mood disorder in the USA. Additionally, the World
Health Organization (WHO) predicts that by 2030,
MDD will be the leading cause of global disability.1 Most
alarming is the fact that the main strategy of MDD man-
agement, which is antidepressant medication, shows only
modest efficacy: 40% of patients do not respond to cur-
rent treatments and often experience undesirable side
effects.2 Moreover, medication response is lengthy, with
high rates of relapse and treatment resistance.3
MDD’s underlying molecular mechanisms are still to
be unraveled. Novel technologies such as omics-based
platforms may offer new insights into the pathobiologic
core of MDD, as well as the possibility of discovering
potential diagnostic, therapeutic, and disease course bio-
marker candidates.4
Proteomics
Proteomics is the science that emerged from the term
“proteome,”5 which can be defined as the set of
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Omics technologies emerged as complementary strategies
to genomics in the attempt to understand human ill-
nesses. In general, proteomics technologies emerged ear-
lier than those of metabolomics for major depressive dis-
order (MDD) research, but both are driven by the
identification of proteins and/or metabolites that can
delineate a comprehensive characterization of MDD’s mol-
ecular mechanisms, as well as lead to the identification of
biomarker candidates of all types—prognosis, diagnosis,
treatment, and patient stratification. Also, one can
explore protein and metabolite interactomes in order to
pinpoint additional molecules associated with the disease
that had not been picked up initially. Here, results and
methodological aspects of MDD research using pro-
teomics, metabolomics, and protein interactomics are
reviewed, focusing on human samples.  
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expressed protein by a cell, tissue, or organism, in a given
moment, under a determined condition. Nowadays pro-
teomics approaches much more than the study of the
proteome, including the characterization and identifica-
tion of post-translational modifications, protein-protein
interaction, protein turnovers, and more. 
Methodologies for proteome investigations
The identification, and eventually the quantification, of
a given proteome of interest is the most popular tool in
the proteomics toolbox. Two-dimensional gel elec-
trophoresis (2DE) combined with mass spectrometry
(MS) had been the basis of proteomics since its begin-
ning. Recently, the combination 2DE-MS has been
replaced gradually by shotgun proteomics (or shotgun–
mass spectrometry [shotgun-MS]). Both approaches
have advantages and disadvantages, and their combina-
tion seems to be the best strategy. 
Two-dimensional gel electrophoresis combined with mass
spectrometry 
The principle of 2DE, a methodology developed back in
the 1970s6 and further optimized since then,7-10 is to sep-
arate the proteins by two of their physicochemical char-
acteristics. First, using isoelectrofocusing (IEF), proteins
are separated according to their isoelectric point (pI) in
a gel with an immobilized pH gradient. These proteins
are washed in sodium dodecyl sulfate (SDS) solution
and then separated according to their apparent molecu-
lar weight using SDS-polyacrylamide gel electrophore-
sis (SDS-PAGE). Proteins may be stained after elec-
trophoresis, or even labeled with fluorescent dyes prior
to electrophoresis, also known as 2D fluorescence dif-
ference gel electrophoresis (2D-DIGE).11 Each sample
has a proteome defined in a gel. Each gel is filled with
dots, technically called spots, which can be compared
across different gels according to their density, calculated
with the help of computational software according to
their intensity and volume. Spots of interest can be
excised from the gels, digested, and identified by MS. 
In the 1990s, the 2DE-MS approach was an attractive
technique to separate thousands of proteins using rela-
tively low amounts of samples. Nowadays, shotgun-MS
techniques, which started to emerge at the end of the
1990s,12 require two orders of magnitude less of samples,
and the material is handled in a more automated man-
ner. Moreover, some of 2DE’s drawbacks, such as the
potential overlap of proteins in a single spot, as well as
the resolution of low abundant, hydrophobic, very acidic,
very basic, very small, and very large proteins, can be
avoided by shotgun-MS.
Shotgun-MS
In shotgun-MS approaches, gels are not needed to sep-
arate the proteins prior to their identification. The basic
principle is to digest the whole proteome of interest and
inject in a system that possesses high-performance liq-
uid chromatography (HPLC) coupled online to a mass
spectrometer (LC-MS). Data from shotgun-MS, which
consists of chromatograms attached to mass spectra, are
analyzed by complex computational algorithms to recon-
struct the protein sequences based in the masses of all
peptides measured and fragmented. This process is
known as “bottom-up proteomics.” MS-based pro-
teomics have rapidly developed in the past 10 years.
Nowadays, a single LC-MS experiment is able to reveal
3000 to 7000 proteins in an hour, which would only be
doable— if at all—by combining 2DE-MS over some
weeks of work. 
For proteome quantitation, there are several alter-
natives that can be taken into consideration13 for a given
LC-MS experiment, such as stable isotope labeling in
vitro (ie, isotope-coded affinity tags [ICAT]14 and iso-
baric tags for relative and absolute quantitation
[iTRAQ]15) or even in vivo (ie, stable isotope labeling
by/with amino acids in cell culture [SILAC]16 or stable
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2DE two-dimensional gel electrophoresis
GC gas chromatography
HPLC high-performance liquid 
chromatography
iTRAQ isobaric tags for relative and absolute 
quantitation
LC-MS high-performance liquid chromatography–
mass spectrometer
MDD major depressive disorder
NMR Nuclear magnetic resonance spectroscopy
PGDS prostaglandin D2 synthase
PI3K-mTOR phosphatidylinositol 3-kinase and the 
mammalian target of rapamycin
SDS sodium dodecyl sulfate
SRM selected reaction monitoring
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isotope labeling in mammals [SILAM]), as well as
diverse label-free approaches.17
Shotgun-MS still presents difficulty in representing
hydrophobic and low abundant proteins depending on
the type of sample preparation and MS acquisition.
Moreover, information of intact proteins is lost by con-
ventional bottom-up proteomics, which can be repre-
sented by 2DE, as well as the characterization of certain
protein post-translational modifications. 
Proteome findings in patients with depression
Brain tissue and cerebrospinal fluid
Surprisingly, and unlike other psychiatric disorders such
as schizophrenia,18,19 only one research group focused
their efforts on the large-scale proteome investigation of
postmortem human brains from depressed patients,
through two articles. Samples from the dorsolateral pre-
frontal cortex (DLPFC) of 24 patients with MDD were
compared with 12 controls using a shotgun label-free
approach. Some of the protein candidates were further
validated by selected reaction monitoring (SRM).
Several biological functions were associated with MDD,
such as energy metabolism, cellular transport, and cell
communication and signaling.20 Energy metabolism has
already been described for a long time as a pattern for
psychiatric disorders in general, via several different
techniques.21-23 However, it has been possible to delineate
exactly which energy metabolism pathways are more
involved in each disorder, by using proteomics.
Glycolysis is the main affected pathway in schizophre-
nia brains,24 whereas in MDD, oxidative phosphorylation
is the most affected. Not only have several subunits of
oxidative phosphorylation complexes been shown to be
expressed differentially, but adenosine triphosphate
(ATP) levels were also determined to be lower in
MDD.20 Additionally, a proteomic study of a preclinical
model for anxiety has shown both pathways to be dif-
ferentially regulated.25
Of the 24 MDD samples analyzed in the proteome
study cited above, 12 presented with psychosis as onet of
their symptoms (MDD-P), in contrast to the remaining
12 (MDD-NP). Interestingly, when the factor “psy-
chosis” was taken into consideration, the proteome dif-
ferences between MDD-P vs controls, or vs MDD-NP
revealed similarities in proteins differentially expressed
in schizophrenia, including glycolysis enzymes, which
were not present when all MDD patients were com-
pared with controls.20
In the MDD brain, the histidine triad nucleotide-
binding protein 1 (HINT1) was found to be increased,
as confirmed by SRM-MS. On the other hand, HINT1
levels were found to be decreased in schizophrenia in
the DLPFC.26 It is important to note that when MDD
patients were compared separately according to their
psychotic symptoms, HINT1 was only observed as
increased in MDD-P subjects. This protein has been
associated with antidepressant- and anxiolytic-like
effects,27 and is thought to play a role in postsynaptic
dopamine transmission. Additionally, HINT1 has been
hypothesized to interfere with hypothalamic-pituitary-
adrenal axis function.27,28
A second large-scale MS-based investigation of
MDD brains was a phosphoproteome analysis also in
the DLPFC. Ninety out of 802 proteins presented dif-
ferential levels of phosphorylation in MDD compared
with controls. The great majority of these proteins were
associated with synaptic transmission, such as two sub-
units of clathrin and two subunits of spectrin, synapsin,
and dynamin, in addition to proteins such as actin,
actinin, and internexin, which are associated with cellu-
lar architecture.29 These results align with the MDD pro-
teomic study, which also shows a dysregulation of synap-
tic-related proteins,20 especially those associated with
soluble NSF attachment receptor (SNARE) function,
such as synaptosomal-associated protein 25 (SNAP25),
γ-aminobutyric acid receptor–associated protein-like 2
(GABARAPL2), and syntaxin 1B (STX1B). Synapsin I
(SYN1), which also plays a role in SNARE function, has
been found to be differentially phosphorylated in MDD
brains.
Another two reports from other research groups pre-
sent proteome investigations of MDD brain, but these
studies focused on the analyses of schizophrenic brains,
using MDD and bipolar disorder samples as controls for
specificity. The proteomes of the frontal cortex (FC)30 and
anterior cingulate cortex (ACC)31 from depressed
patients have been subjected to 2DE-based proteomic
analyses, revealing an altered expression of dihydropy-
rimidinase-like 2 (DPYSL2). DPYSL2, also known as col-
lapsin response mediator protein 2 (CRMP2), plays a
range of roles, including participation in the development
of the central nervous system by regulating axonal guid-
ance, neuronal growth cone collapse, and cell migration.32
Additionally, energy metabolism–related proteins such
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as carbonic anhydrase (CA2) and aldolase C (ALDOC)
were found to be altered in both brain regions. 
A study on schizophrenia biomarkers analyzed the
cerebrospinal fluid (CSF) of 16 MDD patients.33 These
were classified as psychotic and nonpsychotic, and ana-
lyzed separately in order to observe whether the bio-
markers identified for schizophrenia were specific, or if
they were associated with acute psychosis. The authors
concluded that the proteomic signature was specific
enough to identify schizophrenia, but the number of psy-
chotic MDD cases was too small. 
Using the traditional proteomic combination of 2DE-
MS and shotgun-MS, the proteomes of the CSF from 12
MDD patients and 12 controls were compared in quan-
tity and phosphorylation levels.34 Eleven proteins were
found to be differentially expressed by 2DE, and addi-
tionally by shotgun-MS.25 Proteins were involved in neu-
roprotection, neurodevelopment, and sleep regulation.
A particular set of proteins involved in energy metabo-
lism—anti–pigment epithelium derived factor (PEDF),
apolipoprotein E (ApoE), prostaglandin D2 synthase
(PGDS), and cystatin C—were chosen to be validated by
Western blot due to the association of MDD with meta-
bolic syndrome. Interestingly, PGDS, which was found to
be downregulated in this study, was observed to be
upregulated in the CSF of schizophrenia patients.35
Differences in phosphorylation levels were observed for
16 proteins, some of which also had altered expression. 
Blood
Unlike with preclinical models,36,37 few efforts have been
so far invested in identifying proteomic differences in
the blood of MDD patients in comparison with healthy
subjects. The blood plasma proteome from 21 first-onset
drug-naive MDD patients was compared with the same
number of controls, employing a shotgun proteomics
platform combined with iTRAQ in a hypothesis-free
manner.38 Further validations of protein candidates were
performed by Western blot and enzyme-linked
immunoadsorbent assay (ELISA). The modest number
of 9 proteins were found to be differentially expressed
in MDD patients, being mostly involved in lipid metab-
olism and the immune system, which are postulated to
be involved in the early stages of MDD pathophysiol-
ogy.38 The importance of this study is not only to reveal
potential biomarker candidates,39 but also in the com-
prehension of MDD as a systemic disorder.
Mononuclear cells
There is a need to improve the understanding of the
molecular mechanisms triggered by successful antide-
pressant treatment. With this in mind, a mass spectrom-
etry-based proteome analysis of blood mononuclear
cells (MNC) collected from inpatients upon admission
(T0) and after 6 weeks of psychopharmacological treat-
ment (T6) was performed. Patients were classified as
good or poor responders, and their proteomic profiles
were compared at T0. 
Proteins related to integrin and Ras signaling exhib-
ited different MNC expression levels at T0. In addition,
a longitudinal proteomic profiling analysis (T0-T6) to
investigate the biology involved in the antidepressant
treatment response showed that the biological processes
for good and poor responders were similar, but they pre-
sented different patterns of regulation. These results go
along with the implementation of new strategies for a
personalized medicine approaches by predicting which
patients might respond to a specific antidepressant.40
Metabolomics
One of the first reports mentioning the term
“metabolomics” came out in the literature around the
year 2000.41,42 With a similar proposal to proteomics, this
technology emerged as a means of understanding bio-
logical systems and diseases in a large-scale manner,
through the identification of metabolic substrates and
products of a given biochemical system. The technique
of metabolomics may also be of use in the research of
xenobiotics, drugs, and medications.
Considering the metabolome as the metabolic state
of a given physiologic status of a given cell, tissue, or
organism, metabolomics is not only a complementary
tool for understanding proteomics data, but also a disci-
pline that stands on its own, able to reveal biochemical
pathways involved in biological mechanisms of interest,
as well as potential biomarkers.43
Methodologies
Sample preparation
The sample preparation for metabolome analyses is the
most important part of the study. It depends on the
classes of metabolites that one wants to study, for exam-
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ple, general metabolome analyses44 or more target-ori-
ented analyses according to the interest of the study in
detecting hydrophilic45 or hydrophobic46 molecules. Also,
the sample preparation will depend on the type of plat-
form to be employed, which will be discussed ahead. The
most important issue during sample preparation, espe-
cially when a comparative study is performed, is to
assure that samples are collected using a standardized
procedure, in order to capture the same metabolomic
snapshot across all samples to be analyzed. Considering
the very dynamic nature of the products of metabolism,
the metabolome status can change significantly and
rapidly when confronted with any mild environmental
stimulus; this in itself can actually be an interesting
aspect to be explored, ie, metabolites’ turnover rates.47
Nuclear magnetic resonance spectroscopy–based
metabolomics
Nuclear magnetic resonance spectroscopy (NMR) con-
sists of the absorption and re-emission of electromag-
netic radiation by atomic nuclei in a magnetic field.
Molecules, here treated as metabolites, may have their
metabolic fingerprint determined by this process, lead-
ing to their identification and possibly to their quantifi-
cation, in a large-scale, nontargeted, and nondestructive
manner.48 NMR is applicable to the analyses of biofluids,
cell extracts, and cell cultures, and requires almost no
sample preparation.49 The standard approach for
metabolomic analysis using patient’s samples is using
proton NMR (1H NMR), although other nuclides, such
as 2H, 13C, 31P, 15N, and 19F, may by employed for the gen-
eration of additional information.50,51
Mass spectrometry–based metabolomics
MS-based metabolomics may provide a targeted or large-
scale metabolome analysis.52 It has become an indispens-
able tool in metabolome/metabonome analysis53,54 and is
generally combined online with three types of prefrac-
tionation methods: gas chromatography (GC),55 HPLC,56
or capillary electrophoresis (CE).57 As always in analyt-
ical chemistry, each separation method has its advantages
and drawbacks: GC is highly efficient, sensitive, and
reproducible, but can only be performed with volatile
compounds or those that can be made volatile. HPLC
separation may reach a wider range of analytes, even
though its resolution is poorer. In turn, CE may present
superior performance regarding separation than HPLC,
but it is properly applicable to charged analytes.
The advantage of MS lies in its sensitivity and
throughput.58 Fingerprints of metabolites can be deter-
mined for establishing metabolome libraries, which will
facilitate the identification of a given metabolite. 
Metabolome findings in samples from patients with
depression
Although metabolomics studies in depression are rather
recent—the first report came out in 2007 studying
human samples—they have become popular and even
more used in human samples than proteomics. Several
metabolomics studies have been performed in preclini-
cal models of depression.59-62
Brain tissue and CSF
No metabolomic study has been performed in brain tis-
sue from MDD patients thus far. There is one report
with CSF analyses. A targeted metabolomic analysis was
carried out in the CSF of 14 unmedicated MDD
patients, 14 remitted MDD subjects, and 18 healthy con-
trols. Tryptophan, tyrosine, purine, and related pathways
were analyzed, revealing higher levels of methionine,
and reduced levels of tryptophan and tyrosine in remit-
ted patients. Additionally, the same group presented
altered methionine-to-glutathione ratios, suggesting
alterations in methylation and oxidative stress pathways.
Unmedicated MDD subjects also showed alterations in
these same metabolites, but not to a statistical level.63
Blood (and urine)
Blood plasma was collected from 9 elderly MDD
patients, 11 remitted patients, and 10 mentally healthy
subjects. After screening over 800 metabolites by GC-
MS, results suggested that higher concentrations of lipid
metabolites and neurotransmitters, such as dicarboxylic
fatty acids, glutamate, and aspartate, are associated with
MDD. Interestingly, these differences are less prominent
in treated patients, who presented a metabolomic panel
more similar to that of control subjects.64 The panel of
blood plasma metabolites associated with depression
changed when a second variable came into play. While
in the first study, elderly patients were considered, in this
other study MDD patients with heart failure were com-
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pared with nondepressed heart failure patients. Here,
GC-MS and LC-MS metabolomics platforms revealed
differential concentrations of certain amino acids, such
as glutamate, aspartate, and cysteine. Moreover, as in the
study with elderly patients, a dysfunction of fatty acid
metabolism was observed, suggesting this pathway as
part of a biosignature of MDD.65
Aiming to implement the metabolome of MDD
patients as means of diagnosis, the plasma metabolomes
of MDD patients and healthy controls were compared
using NMR-based metabolomics. The analyses of 58
first-episode drug-naïve depressed patients, compared
with 42 controls, revealed a panel of metabolites that
could distinguish these two groups in a second round of
experiments, using 26 samples in a blind manner.66
Similarly, the urine metabolomes of 82 first-episode
drug-naïve MDD patients have been compared with 82
healthy controls by NMR-based metabolomics, reveal-
ing differences in concentration of malonate, formate,
N-methylnicotinamide, m-hydroxyphenylacetate, and
alanine. In a multivariate analysis, these metabolites
could separate MDD from healthy controls. This same
panel of metabolites was then analyzed in a second set
of samples composed of 44 MDD patients and 52
healthy controls in a blind manner, achieving a similar
level of group distinction.67 These two studies present
promising findings, especially considering their capac-
ity to distinguish MDD groups in a blind manner.
However, urine studies must be performed, keeping in
mind that future applications of these results demand
the establishment of standard operating procedures for
sample collection, due to the large metabolic variation
in urine composition. 
Considering that a significant number of MDD
patients do not respond to the current medications, the
likelihood for a successful response has been evaluated
using metabolomics. Serum metabolomes from 43 MDD
patients treated with sertraline were compared before
the initiation of treatment, with a group of 46 subjects
receiving a placebo, using liquid chromatography elec-
trochemical array. The metabolome profiles partially
separated responders from nonresponders by employ-
ing multivariate analyses. The metabolites that con-
tributed the most to the separation of responders from
nonresponders were phenylalanine, tryptophan, purine,
and tocopherol. Additionally, dihydroxyphenylacetic
acid, tocopherols, and serotonin were more relevant to
the separation of the medication and placebo groups.68
In a more extensive study, the metabolome profiles of
the serum from MDD patients treated with sertraline or
placebo have been analyzed and quantified by GC-MS
at three time points: prior to medication, and 1 and 4
weeks after medication. Sertraline- and placebo-induced
differences in metabolites were related to tricarboxylic
acid cycle (TCA), urea cycle, fatty acids and intermedi-
ates of lipid biosynthesis, amino acids, sugars, and gut-
derived metabolites, with more pronounced differences
after 4 weeks. More specifically, sertraline showed effects
on ATP-binding cassette (ABC) and solute transporters,
G signaling molecules, and fatty acid metabolism. The
increasing effect of the drug after 4 weeks of treatment
is in line with the delayed clinical effect of the medica-
tion.69
Results discussed in this topic go towards transla-
tional strategies with the potential of future clinical
implementation. As for most psychiatric disorder stud-
ies, follow-up of these results is necessary.70
Protein interactomics
The concept of the interactome considered here con-
cerns the complete set of molecular interactions of a
given protein in a given cell or other biological environ-
ment. Hence, all proteins, and eventually metabolites,
that interact with a given protein of interest, promoting,
regulating, and inhibiting its activity or expression, is part
of its interactome. Establishing a protein interactome
may be informative about the protein function and all
molecular mechanisms in which it is involved.
Additionally, the study of protein interactomes in dis-
eases may reveal dysfunctional pathways, their regula-
tion, and the possible role that protein partners play in
the disease.71
Methodologies
Protein interactome studies72 have been mainly performed
employing yeast two-hybrid screening (Y2H)73 and tandem
affinity purification (TAP).74,75 Coimmunoprecipitation (co-
IP) has also been used as a reliable method for studying
protein interactomes.76,77 In addition, there have been efforts
invested in the establishment of algorithms that can predict
the network of interactions of a given protein, including its
3D modeling, which is pivotal not only for the characteri-
zation of its roles in the cell, but also to reveal potential tar-
gets for drug discovery and design.78-80
68
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Protein interactome in patients with depression
The phosphatidylinositol 3-kinase and the mammalian
target of rapamycin pathway—PI3K-mTOR—plays a
central role in the therapeutics of MDD through the
activation of immune cells via inflammatory cytokines.81
Thirty-three components of the PI3K-mTOR pathway
have been targeted for a large-scale interactome analy-
sis employing Y2H screen. More than 800 interactions
to the PI3K-mTOR pathway have been identified,
including 67 new interactions. Further validations sug-
gest that deformed epidermal autoregulatory factor-1
(DEAF1) is a substrate for glycogen synthase kinase-3
(GSK3) A and B, and that this protein might be a ther-
apeutic target of lithium treatment for MDD.82
A systematic network and pathway analysis of MDD
candidate genes has been constructed, based on a set of
genes proposed to be associated with MDD in associa-
tion, linkage, and gene expression studies of humans and
animals.83 An overlap of MDD’s molecular features with
schizophrenia has been observed. Moreover, the authors
proposed neurotransmission- and immune system–
related pathways as the most representative biological
processes involved in MDD. Even though these are
processes previously shown as involved in MDD by
other fields of study,84 this in silico interactome study has
pinpointed the role players in the dysregulation of these
pathways, which is an important example of the infor-
mation that omics technologies are able to provide.85
Integration of omics technologies
The overall understanding of a biomolecular system can
be obtained by the integration of large-scale analyses
coming from different sources, such as proteomics,
metabolomics, and protein interactomics. Nowadays,
Figure 1. Protein network suggested by STRING (Search Tool for the Retrieval of INteracting Genes/proteins) for the differentially expressed proteins
found in the dorsolateral prefrontal cortex of depression patients according to previous findings in the literature. Abbreviations: ACOT13, acyl-
CoA thioesterase 13; APOE, apolipoprotein E; ATP51, adenosine triphosphate 51; COX4I1, cytochrome c oxidase subunit IV isoform 1; COX5B,
cytochrome c oxidase subunit Vb; COX7A2, cytochrome c oxidase subunit VIIa polypeptide 2; CSTB, cystatin B (stefin B); CST3, cystatin 3;
CYCS, cytochrome c, somatic; DPYSL2, dihydropyrimidinase-like 2; DPYSL3, dihydropyrimidinase-like 3; HINT1, histidine triad nucleotide-bind-
ing protein 1; HRSP12, heat-responsive protein 12; MAP1LC3A, microtubule-associated proteins 1A/1B light chain 3A; NDUFA2, NADH dehy-
drogenase (ubiquinone) 1 alpha subcomplex subunit 2; NDUFA6, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 6; NDUFA13,
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 13;  NDUFS2, NADH dehydrogenase (ubiquinone) Fe-S protein 2; UQCRFS1,
Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
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considering the huge datasets that can be generated by
each one of these analytical chemistry platforms, several
computational tools and algorithms have been devel-
oped to integrate these results. As an example, the Web-
based tool STRING (Search Tool for the Retrieval of
INteracting Genes/proteins)86 has been used to analyze
the differentially expressed proteins found in the
DLPFC of MDD patients, as described earlier.20 As can
be seen in Figure 1, STRING’s algorithm proposes sev-
eral interactions among these proteins. The greater the
number of colored lines connecting two proteins, the
stronger the suggested evidence of their interaction. 
In this case, some connections are evident: for exam-
ple it is known that the protein subunits of NADH dehy-
drogenase (ubiquinone) are all part of the complex I of
the respiratory chain or the proteins COX, which are
components of cytochrome c oxidase. Other interactions
may be informative: for example, what is the nature of
the connection between HINT1, an antidepressant-asso-
ciated protein, to cytochrome c oxidase? Could this pro-
tein interfere with the mitochondrial metabolism?
It is important to note however, that the so called “inter-
action” may have several different levels of evidence:
briefly, this interaction can be the result of an experimen-
tally proven interaction, the two proteins may have been
mentioned in a given scientific publication, or another
computational algorithm may have suggested their inter-
action. Thus, especially in the last scenario, for which there
is no experimental proof that such interaction really exists,
this data must be interpreted carefully. Informative tools
such as STRING, Cytoscape,87 Ingenuity Pathway
Analyses (Ingenuity® Systems), and Pathway Studio
(Ariadne Genomics) have become popular lately, and
indeed facilitate the understanding of a given molecular
process. However, the final curator of these results is the
researcher using it, and this step is a must. Having estab-
lished a dataset of lines and connections does not mean
that this represents, per se, a meaningful interactome.
Some of the tools mentioned above can also deal
with drug metabolites, and even suggest interactions of
proteins and metabolites of interest with known drugs.
These can be informative pieces of evidence to be fur-
ther investigated in the laboratory, depending on the
nature of the interaction proposed by the computational
tool. Here lies the beauty of the large-scale studies: gen-
erating, with parsimony, new hypotheses to be further
investigated. Further information on integrative systems
biology can be found in refs 88 and 89. 
Conclusions and perspectives
The omics technologies applied to studies of human
samples as discussed here lead to modest, but new,
hypotheses. These have helped the understanding of the
molecular mechanisms of MDD. As discussed above, the
overall dysfunction of oxidative phosphorylation, which
contrasts with the pathways noted in schizophrenia,
together with the differential expression and phospho-
rylation of a number of synaptic proteins, may warrant
further investigation regarding these particular targets.
Data reviewed here must be combined with information
obtained from preclinical models.25,37,80-95 These have the
advantage of showing fewer confounding factors than
human samples. Their limited biomechanical range must
be noted, since not all features of a complex human dis-
ease such as MDD can be considered. Omics technolo-
gies, particularly metabolomics, can also be employed in
the development of innovative medications, which are
urgently needed.96
With regards to biological markers of depression, the
findings are still preliminary.97 In contrast to what was
expected, the identification of such biomarkers seems
to be more complex than anticipated.98-100 An example is
the recent withdrawal of VeriPsych, which was the only
commercially available test biomarker for a psychiatric
condition. The molecular overlap among psychiatric dis-
orders makes the task of developing diagnostic tools
very challenging. MDD patients who present with sim-
ilar symptoms may have completely distinct biochemi-
cal signatures: some may have become depressed due
to immune system–related dysfunctions, while others
may have had their energy metabolism affected.
Additionally, the different biological factors unrelated
to the disease, such as cigarette smoking and alcohol
consumption, must be taken into account carefully.
Among the most wanted biomarkers are those associ-
ated with the prediction of a successful drug response.
MDD treatment is lengthy, and after several weeks,
about 40% of patients do not respond to current med-
ications. The formula “one treatment suits them all”
does not fit. Biomarkers to identify subgroups of
patients and predict therapeutic response are needed to
achieve higher successful treatment rates. Hence, the
identification of treatment biomarkers may enhance
translational and personalized medicine strategies,
which in turn can shape the future for an improved
quality of life of MDD patients. ❏
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Proteómica, metabolómica  e interactómica
proteica en la caracterización de los aspectos
moleculares del trastorno depresivo mayor
Las tecnologías “ómicas” aparecieron como estra-
tegias complementarias a la genómica en el intento
de comprender las enfermedades humanas. Aunque
en general las tecnologías proteómicas surgieron
antes que las metabolómicas en la investigación del
trastorno depresivo mayor (TDM), ambas están
orientadas a la identificación de proteínas y/o meta-
bolitos que permita esbozar una completa caracte-
rización de los mecanismos moleculares del TDM, así
como también llevar a la identificación de biomar-
cadores candidatos de todos los tipos: pronóstico,
diagnóstico, tratamiento y estratificación de pacien-
tes. También se pueden explorar interactomas de
proteínas y metabolitos para precisar moléculas adi-
cionales, asociadas con la enfermedad, que no han
sido identificadas inicialmente. En este artículo se
revisan los resultados y aspectos metodológicos de
la investigación en el TDM que emplea proteómica,
metabolómica e interactómica de proteínas, cen-
trándose en muestras de humanos.   
La protéomique, la métabolomique et 
l’interactomique des protéines pour 
caractériser les aspects moléculaires de 
l’épisode dépressif caractérisé
Les technologies dites « omiques » sont apparues
pour compléter la génomique afin de comprendre
les maladies humaines. D’une façon générale, les
technologies protéomiques sont antérieures aux
métabolomiques dans la recherche sur l’épisode
dépressif caractérisé (EDC) mais les deux sont fon-
dées sur l’identification des protéines et/ou des
métabolites pour définir une description complète
des mécanismes moléculaires de l’EDC et identifier
des biomarqueurs candidats de tout type, pronos-
tique, diagnostique, thérapeutique, et pour la stra-
tification des patients. Il est également possible
d’analyser les interactomes des protéines et des
métabolites afin de repérer d’autres molécules asso-
ciées à la maladie et non détectées au début. Cet
article étudie chez l’homme les résultats et les
aspects méthodologiques de la recherche sur l’EDC
par la protéomique, la métabolomique et l’interac-
tomique des protéines.
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